Gel compositions and methods of use
View Patent ↗Improved topical gel compositions for the treatment of skin disorders are described. The gel compositions contain carbomer and methylparaben, and are substantially free of methylparaben crystalline particles after an extended period of storage.
1. A topical gel composition, comprising:
0.05 to 0.20% (w/w) methylparaben;
a second preservative;
0.80 to 1.50% (w/w) carbomer;
9.0 to 13.0% (w/w) total polyol; and
purified water;
wherein the topical gel composition has a pH of 4.5 to 7.5; and
wherein when the concentration of methylparaben is greater than 0.15% (w/w), the concentration of carbomer is less than 1.25% (w/w).
2. The topical gel composition of claim 1 , comprising about 4.5% to 6.5% (w/w) of a first polyol.
3. The topical gel composition of claim 1 , further comprising an alpha adrenergic receptor agonist.
4. The topical gel composition of claim 3 , wherein the alpha adrenergic receptor agonist is an alpha-1 or alpha-2 adrenergic receptor agonist.
5. The topical gel composition of claim 4 , wherein the alpha adrenergic receptor agonist is selected from the group consisting of oxymetazoline, phenylephrine, methoxyamine, tetrahydrozoline, naphazoline, xylometazoline, epinephrine, and norepinephrine.
6. The topical gel composition of claim 1 , further comprising 0.04 to 0.08% (w/w) of a water dispersible form of titanium dioxide.
7. The topical gel composition of claim 1 , wherein the carbomer is selected from the group consisting of carbomer 934P, carbomer 974P and carbomer 980.
8. The topical gel composition of claim 1 , wherein the second preservative is selected from the group consisting of sodium benzoate, phenoxyethanol, benzyl alcohol, imidazolidinyl urea, and diazolidinyl urea.
9. A topical gel composition, comprising:
0.05 to 0.15% (w/w) methylparaben;
a second preservative selected from the group consisting of sodium benzoate, phenoxyethanol, benzyl alcohol, imidazolidinyl urea and diazolidinyl urea;
0.80 to 1.50% (w/w) carbomer;
4.5 to 6.5% (w/w) propylene glycol;
4.5 to 6.5% (w/w) glycerol; and
purified water;
wherein the pH of the topical gel composition is adjusted to 5.0 to 6.5 by an adequate amount of sodium hydroxide aqueous solution.
10. The topical gel composition of claim 9 , wherein the second preservative is phenoxyethanol, present at an amount greater than 0.3% (w/w) of the total weight of the topical gel composition.
11. The topical gel composition of claim 9 , further comprising 0.04 to 0.08% (w/w) of a water dispersible form of titanium dioxide.
12. The topical gel composition of claim 9 , further comprising an alpha adrenergic receptor agonist.
13. The topical gel composition of claim 12 , wherein the alpha adrenergic receptor agonist is an alpha-1 or alpha-2 adrenergic receptor agonist.
14. The topical gel composition of claim 13 , wherein the alpha adrenergic receptor agonist is selected from the group consisting of oxymetazoline, phenylephrine, methoxyamine, tetrahydrozoline, naphazoline, xylometazoline, epinephrine, and norepinephrine.
15. A method of treating or preventing a skin disorder in a subject, comprising topically administering to a skin area of the subject the topical gel composition of claim 1 , wherein the gel composition further comprises an alpha adrenergic receptor agonist selected from the group consisting of oxymetazoline, phenylephrine, methoxyamine, tetrahydrozoline, naphazoline, xylometazoline, epinephrine, and norepinephrine, and wherein the skin area is, or is prone to be, affected by the skin disorder.
16. The method of claim 15 , wherein the skin disorder is rosacea, erythema of rosacea, telangiectasia, psoriasis, purpura, erythema of acne, eczema, non-rosacea-related inflammation of the skin, flushing, skin sagging, creasing and/or wrinkling, or a symptom associated therewith.
17. A method of treating or preventing a skin disorder in a subject, comprising topically administering to a skin area of the subject the topical gel composition of claim 9 , wherein the gel composition further comprises an alpha adrenergic receptor agonist selected from the group consisting of oxymetazoline, phenylephrine, methoxyamine, tetrahydrozoline, naphazoline, xylometazoline, epinephrine, and norepinephrine, and wherein the skin area is, or is prone to be, affected by the skin disorder.
18. The method of claim 17 , wherein the skin disorder is rosacea, erythema of rosacea, telangiectasia, psoriasis, purpura, erythema of acne, eczema, non-rosacea-related inflammation of the skin, flushing, skin sagging, creasing and/or wrinkling, or a symptom associated therewith.